JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $37 | -100.0% | 33,430 | 0.0% | 0.00% | -60.0% |
| Q3 2022 | $78,000 | -22.8% | 33,430 | 0.0% | 0.01% | -37.5% |
| Q2 2022 | $101,000 | +32.9% | 33,430 | +227.7% | 0.01% | -20.0% |
| Q3 2021 | $76,000 | -59.4% | 10,200 | -62.3% | 0.01% | -84.1% |
| Q2 2020 | $187,000 | -2.6% | 27,090 | -33.0% | 0.06% | -22.2% |
| Q1 2020 | $192,000 | -13.1% | 40,410 | +59.7% | 0.08% | +22.7% |
| Q4 2019 | $221,000 | +163.1% | 25,310 | 0.0% | 0.07% | +112.9% |
| Q3 2019 | $84,000 | -42.1% | 25,310 | -13.8% | 0.03% | -42.6% |
| Q2 2019 | $145,000 | +64.8% | 29,360 | +107.0% | 0.05% | +8.0% |
| Q1 2019 | $88,000 | – | 14,182 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |